Baird Downgrades Amylyx Pharma to Neutral, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty downgraded Amylyx Pharma (NASDAQ:AMLX) from Outperform to Neutral and significantly reduced the price target from $37 to $4, indicating a bearish outlook on the company's stock.
March 11, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Amylyx Pharma was downgraded by Baird from Outperform to Neutral, with a drastic reduction in price target from $37 to $4.
The downgrade from Outperform to Neutral by a prominent analyst, along with a significant reduction in the price target, suggests a bearish outlook on Amylyx Pharma's stock. This is likely to negatively impact investor sentiment and could lead to a decrease in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100